Volume : 10, Issue : 05, May – 2023

Title:

61.OUTCOME & PROGNOSIS OF HEMATOPOIETIC STEM CELL TRANSPLANTATION
‬

Authors :

Banan Matuq Aloufi, Rana Matouq Alaofi, Rahaf Matoug Alofi

Abstract :

Introduction: Hematopoietic stem cell transplant (HPSCT) specifically involves transplanting healthy stem cells from the bone marrow to the recipient with depleted bone marrow. If the donor and recipient are the same individuals, it’s known as autologous and allogenic if they are different but of the same species. Donor cord blood is also sourced for this procedure. HPSCT can be used as bone marrow replacement therapy for certain extreme diseases, such as severe aplastic anemia, sickle cell disease, and cancers. This review will focus on its outcome and prognosis.
Aim of the Study: This review aims to discuss the outcome and prognosis of Hematopoietic stem cell transplantation.
Methodology: Comprehensive research of Hematopoietic stem cell transplant outcome and prognosis. The PUBMED search engine was the database used for the search process, with articles collected from 1957 to 2023. The term used in the search were: Hematopoietic stem cell transplant (HPSCT), outcome, prognosis, HLA typing, Engraftment, Conditioning
Conclusion: The hematopoietic stem cell transplant procedure is usually reserved for some instances of cancer and other extreme hematological diseases. The procedure carries a huge risk for complications which also can be fatal. There has been significant progress in the outcome and prognosis of HPSCT over the years, but much room remains for researchers and clinicians alike.
Keywords: Hematopoietic stem cell transplant (HPSCT), outcome, prognosis, HLA typing, Engraftment, Conditioning

Cite This Article:

Please cite this article in press Banan Matuq Aloufi et al,. Outcome & Prognosis Of Hematopoietic Stem Cell Transplantation., Indo Am. J. P. Sci, 2023; 10 (05).

Number of Downloads : 10

References:

1. Thomas E D, Lochte Jr H L, Lu W C, & Ferrebee J W (1957). Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. New England Journal of Medicine, 257(11), 491-496.
2. Thomas E D, Buckner C D, Clift R A, Fefer A, Johnson F L, Neiman P E, & Weiden P L (1979). Marrow transplantation for acute nonlymphoblastic leukemia in first remission. New England Journal of Medicine, 301(11), 597-599.
3. Henig I, & Zuckerman T (2014). Hematopoietic stem cell transplantation—50 years of evolution and future perspectives. Rambam Maimonides medical journal, 5(4).
4. Khaddour K, Hana C K, & Mewawalla P (2021). Hematopoietic stem cell transplantation. In StatPearls [internet]. StatPearls Publishing.
5. Hierlmeier S, Eyrich M, Wölfl M, Schlegel P G, & Wiegering V (2018). Early and late complications following hematopoietic stem cell transplantation in pediatric patients–A retrospective analysis over 11 years. PLoS One, 13(10), e0204914.
6. Frietsch J J, Flossdorf S, Beck J F, Kröger N, Fleischhauer K, Dreger P, & Hilgendorf I (2023). Outcomes after allogeneic haematopoietic stem cell transplantation in young adults in Germany. British Journal of Haematology, 201(2), 308-318.
7. Rafiee M, Abbasi M, Rafieemehr H, Mirzaeian A, Barzegar M, Amiri V, & Mohammadi M H (2021). A concise review on factors influencing the hematopoietic stem cell transplantation main outcomes. Health Science Reports, 4(2), e282.
8. Kekre N, & Antin J H (2014). Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist. Blood, The Journal of the American Society of Hematology, 124(3), 334-343.
9. Mayor N P, Hayhurst J D, Turner T R, Szydlo R M, Shaw B E, Bultitude W P, & Marsh S G (2019). Recipients receiving better HLA-matched hematopoietic cell transplantation grafts, uncovered by a novel HLA typing method, have superior survival: a retrospective study. Biology of Blood and Marrow Transplantation, 25(3), 443-450.
10. Persaud S P, Cooper M L, Rettig M P, & DiPersio J F (2018). Conditioning for hematopoietic stem cell transplantation using antibody-drug conjugate targeting CD45 permits engraftment across immunologic barriers. Blood, 132, 2035.
11. Duggan P R, Guo D, Luider J, Auer I, Klassen J, Chaudhry A, & Stewart D A (2000). Predictive factors for long-term engraftment of autologous blood stem cells. Bone marrow transplantation, 26(12), 1299-1304.
12. Bornhäuser M, Schliemann C, Schetelig J, Röllig C, Kramer M, Glass B, & Stelljes M (2023). Allogeneic hematopoietic cell transplantation vs standard consolidation chemotherapy in patients with intermediate-risk acute myeloid leukemia: a randomized clinical trial. JAMA oncology, 9(4), 519-526.
13. Du J, Yu D, Han X, Zhu L, & Huang Z (2021). Comparison of allogeneic stem cell transplant and autologous stem cell transplant in refractory or relapsed peripheral T-cell lymphoma: a systematic review and meta-analysis. JAMA Network Open, 4(5), e219807-e219807.
14. Chevallier P, Labopin M, Socie G, Rubio M T, Blaise D, Vigouroux S, & Mohty M (2015). Comparison of umbilical cord blood allogeneic stem cell transplantation vs. auto‐SCT for adult acute myeloid leukemia patients in second complete remission at transplant: a retrospective study on behalf of the SFGM‐TC. European journal of haematology, 94(5), 449-455.
15. Cutler C, Li S, Ho V T, Koreth J, Alyea E, Soiffer R J, & Antin J H (2007). Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood, 109(7), 3108-3114.